Literature DB >> 23179762

Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma.

Hiroshi Kitamura1, Toshihiko Torigoe, Yoshihiko Hirohashi, Hiroko Asanuma, Ryuta Inoue, Sachiyo Nishida, Toshiaki Tanaka, Naoya Masumori, Noriyuki Sato, Taiji Tsukamoto.   

Abstract

Survivin, a member of the inhibitor of apoptosis protein gene family, inhibits apoptosis and promotes mitosis. We determined whether nuclear or cytoplasmic localization of survivin could predict survival of patients with upper urinary tract urothelial carcinoma (UUTUC). Immunohistochemical staining for survivin was carried out on archival specimens from 125 consecutive patients with UUTUC who underwent radical nephroureterectomy. Nuclear and cytoplasmic staining of survivin was scored and compared with clinicopathologic features and cancer-specific survival (CSS). Nuclear expression of survivin was significantly correlated with tumor grade (p < 0.001), lymphovascular invasion (p = 0.022) and poor survival with an estimated 5-year CSS probability of 54 % for tumors with nuclear expression of survivin vs. 73 % for those without nuclear expression of survivin (hazard ratio = 2.19; 95 % confidence interval = 1.02-4.70; p = 0.043). The 5-year cancer-specific survival rates of patients with cytoplasmic survivin-negative and -positive tumors were 66 and 67 %, respectively. There was no difference in survival between patients with cytoplasmic survivin-negative tumors and those with cytoplasmic survivin-positive tumors. Using univariate analysis, nuclear survivin expression, tumor grade, pathological T stage, pathological N stage, and lymphovascular invasion were the predictive variables for CSS. In contrast, cytoplasmic survivin expression had no prognostic relevance. These data suggest that nuclear accumulation of survivin represents biologic aggressiveness and that nuclear survivin is a negative prognostic marker in patients with resected UUTUC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179762     DOI: 10.1007/s00428-012-1343-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  46 in total

1.  Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract.

Authors:  In Gab Jeong; Sung Han Kim; Hwang Gyun Jeon; Baek Hee Kim; Kyung Chul Moon; Sang Eun Lee; Eunsik Lee
Journal:  Hum Pathol       Date:  2009-01-20       Impact factor: 3.466

2.  Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder.

Authors:  Wu Yin; Ni Chen; Yutao Zhang; Hao Zeng; Xueqin Chen; Yongtao He; Xiaojie Wang; Qiao Zhou
Journal:  Mod Pathol       Date:  2006-08-04       Impact factor: 7.842

3.  High nuclear expression of the apoptosis inhibitor protein survivin is associated with disease recurrence and poor prognosis in laryngeal basaloid squamous cell carcinoma.

Authors:  Gino Marioni; Giancarlo Ottaviano; Rosario Marchese-Ragona; Luciano Giacomelli; Andy Bertolin; Davide Zanon; Filippo Marino; Alberto Staffieri
Journal:  Acta Otolaryngol       Date:  2006-02       Impact factor: 1.494

4.  Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.

Authors:  Lilach Kleinberg; Vivi Ann Flørenes; Ilvars Silins; Kristiane Haug; Claes G Trope; Jahn M Nesland; Ben Davidson
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

5.  Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients.

Authors:  Mesut Remzi; Andrea Haitel; Vitaly Margulis; Pierre Karakiewicz; Pierre Karakiewizc; Francesco Montorsi; Eiji Kikuchi; Richard Zigeuner; Alon Weizer; Christian Bolenz; Karim Bensalah; Nazareno Suardi; Jay D Raman; Yair Lotan; Matthias Waldert; Casey K Ng; Mario Fernández; Theresa M Koppie; Philipp Ströbel; Wareef Kabbani; Masaru Murai; Cord Langner; Marco Roscigno; Jeffrey Wheat; Charles C Guo; Christopher G Wood; Shahrokh F Shariat
Journal:  BJU Int       Date:  2008-10-16       Impact factor: 5.588

Review 6.  Molecular and histological markers in urothelial carcinomas of the upper urinary tract.

Authors:  Stephanie Eltz; Eva Comperat; Olivier Cussenot; Morgan Rouprêt
Journal:  BJU Int       Date:  2008-04-02       Impact factor: 5.588

7.  Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth?

Authors:  Woo Sung Moon; Andrzej S Tarnawski
Journal:  Hum Pathol       Date:  2003-11       Impact factor: 3.466

8.  Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining.

Authors:  Lazaros Skagias; Ekaterini Politi; Andreas Karameris; Dimitrios Sambaziotis; Athanasios Archondakis; Apostolos Ntinis; Iraklis Moreas; Olympia Vasou; Helen Koutselini; Efstratios Patsouris
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

9.  Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients.

Authors:  Ching-Chia Li; Tu-Hao Chang; Wen-Jeng Wu; Hung-Lung Ke; Shu-Pin Huang; Pei-Chien Tsai; Shun-Jen Chang; Jung-Tsung Shen; Yii-Her Chou; Chun-Hsiung Huang
Journal:  Eur Urol       Date:  2008-01-28       Impact factor: 20.096

10.  The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy.

Authors:  Wei-Ming Li; Ching-Chia Li; Hung-Lung Ke; Wen-Jeng Wu; Chun-Nung Huang; Chun-Hsiung Huang
Journal:  J Urol       Date:  2009-06-13       Impact factor: 7.450

View more
  8 in total

1.  Assessment of Relationship Between Expression of Survivin Protein and Histopathology Diagnosis and Malignancy Severity in Colon Specimen.

Authors:  Amin Jourabchin; Tahereh Mazoochi; Hamed Haddad Kashani; Tahereh Khamechian
Journal:  J Gastrointest Cancer       Date:  2020-03

2.  Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.

Authors:  Akimasa Hayashi; Teppei Morikawa; Taketo Kawai; Haruki Kume; Shumpei Ishikawa; Yukio Homma; Masashi Fukayama
Journal:  Virchows Arch       Date:  2014-01-21       Impact factor: 4.064

3.  Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma.

Authors:  Serkan Senol; Asif Yildirim; Bahar Ceyran; Fatih Uruc; Ebru Zemheri; Seyma Ozkanli; Ibrahim Akalin; Ismail Ulus; Turhan Caskurlu; Abdullah Aydin
Journal:  Bosn J Basic Med Sci       Date:  2015-08-19       Impact factor: 3.363

4.  Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma.

Authors:  Michiko Shintani; Akiko Sangawa; Naoki Yamao; Shingo Kamoshida
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

5.  Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Yao-Kuang Wu; Chun-Yao Huang; Mei-Chen Yang; Chou-Chin Lan; Chih-Hsin Lee; Err-Cheng Chan; Kuei-Tien Chen
Journal:  Med Oncol       Date:  2014-06-25       Impact factor: 3.064

6.  Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.

Authors:  Annelies W Turksma; Hetty J Bontkes; Janneke J Ruizendaal; Kirsten B J Scholten; Johanneke Akershoek; Shakila Rampersad; Laura M Moesbergen; Saskia A G M Cillessen; Saskia J A M Santegoets; Tanja D de Gruijl; C René Leemans; Chris J L M Meijer; Erik Hooijberg
Journal:  J Transl Med       Date:  2013-06-20       Impact factor: 5.531

7.  Clinical significance of survivin expression in patients with urothelial carcinoma.

Authors:  Hsin-An Chen; Chih-Ming Su; Hsiao-Yen Hsieh; Chun-Liang Tung; Cheng-Da Hsu; Yuan-Hung Wang; Cheng-Huang Shen
Journal:  Dis Markers       Date:  2014-02-05       Impact factor: 3.434

8.  Chemotherapy enhances cross-presentation of nuclear tumor antigens.

Authors:  Chidozie C Anyaegbu; Richard A Lake; Kathy Heel; Bruce W Robinson; Scott A Fisher
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.